Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- University of Southern California
- Study ID
- NCT00183976
- Phase
- PHASE2
- Status
- Terminated
Conditions
- Burkitt Lymphoma
- Non-Hodgkin's Lymphoma
- Primary Effusion Lymphomas
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
Study Details
This study is for patients who have been treated before and either the treatment did not work or the lymphoma has come back.
Key Dates
- Start date
- Apr 30, 2005
- Status verified
- May 2006
- Primary completion
- Sep 30, 2005
- Completion
- Jan 31, 2006
Study Design
- Enrollment
- 15 participants
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| USC/Norris Comprehensive Cancer Center and Hospital | Los Angeles | California | 90033 | - |
Find similar trials in Los Angeles, CA
Related Studies
- ID Of Prognostic Factors In Mycosis Fungoides/Sezary SyndromeRecruiting · Stanford University · Duarte, California
- Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin LymphomaPHASE1 · Recruiting · C. Babis Andreadis · San Francisco, California
- AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell LymphomasPHASE1 · Recruiting · Stanford University · Palo Alto, California
- T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)PHASE1/PHASE2 · Recruiting · Estrella Biopharma, Inc. · Sacramento, California